Calcitonin oral - Takeda
Latest Information Update: 25 Sep 2021
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Shire
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 02 Jun 1998 Suspended-Preclinical for Postmenopausal osteoporosis in United Kingdom (PO)
- 19 Feb 1998 Preclinical development for Postmenopausal osteoporosis in United Kingdom (PO)